Evaluation of an individualized probability index of MRI lesion counts for monitoring patient safety in phase II multiple sclerosis clinical trials

被引：0
|
作者：
Zhao, Y. [1 ]
Traboulsee, A. [1 ]
Li, D. K. B. [1 ]
Riddehough, A. [1 ]
Tam, R. [1 ]
Petkau, A. J. [1 ]
机构：
[1] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：499 / 499
页数：1
相关论文
共 50 条
  • [1] Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis
    Riddell, C. A.
    Zhao, Y.
    Li, D. K. B.
    Petkau, A. J.
    Riddehough, A.
    Cutter, G. R.
    Traboulsee, A.
    [J]. NEUROLOGY, 2011, 77 (24) : 2089 - 2096
  • [2] Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials
    Sormani, MP
    Bruzzi, P
    Miller, DH
    Gasperini, C
    Barkhof, F
    Filippi, L
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 163 (01) : 74 - 80
  • [3] Statistical Efficiency of Phase II Multiple Sclerosis Clinical Trials with Different MRI Scanning Frequencies
    Zhao, Y.
    Chen, J.
    Li, D. K. B.
    Riddehough, A.
    Traboulsee, A.
    Petkau, A. J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 680 - 680
  • [4] Validity of brain MRI as the primary outcome criterion in multiple sclerosis phase II clinical trials
    Liedtke, W
    Limmroth, V
    [J]. ANNALS OF NEUROLOGY, 1996, 39 (02) : 276 - 276
  • [5] Further investigation of safety monitoring guidelines based on magnetic resonance imaging lesion activity in multiple sclerosis clinical trials
    Dong, Jing
    Zhao, Yinshan
    Petkau, A. John
    Li, David K. B.
    Riddehough, Andrew
    Traboulsee, Anthony
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (01) : 101 - 104
  • [6] Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials
    Sormani, Maria Pia
    Pardini, Matteo
    [J]. NEUROTHERAPEUTICS, 2017, 14 (04) : 924 - 933
  • [7] Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials
    Maria Pia Sormani
    Matteo Pardini
    [J]. Neurotherapeutics, 2017, 14 : 924 - 933
  • [8] Sample size calculations for paediatric multiple sclerosis clinical trials using clinical relapse and MRI lesion endpoints
    Verhey, L. H.
    Signori, A.
    Arnold, D. L.
    Bar-Or, A.
    Sadovnick, A. D.
    Marrie, R. A.
    Banwell, B.
    Sormani, M. P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 92 - 92
  • [9] Daclizumab phase II trial in relapsing and remitting multiple sclerosis - MRI and clinical results
    Rose, J. W.
    Burns, J. B.
    Bjorklund, J.
    Klein, J.
    Watt, H. E.
    Carlson, G.
    [J]. NEUROLOGY, 2007, 69 (08) : 785 - 789
  • [10] An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials
    Brutti, P.
    Gubbiotti, S.
    Sambucini, V.
    [J]. STATISTICS IN MEDICINE, 2011, 30 (14) : 1648 - 1664
12345